)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kezar Life Sciences
Kezar Life Sciences (KZR) investor relations material
Kezar Life Sciences has been acquired by Aurinia Pharmaceuticals Inc
Kezar Life Sciences Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary11 May, 2026
Executive summary
Entered into a Merger Agreement on March 30, 2026, with Aurinia Pharma U.S., offering $6.955 per share plus a contingent value right (CVR) per share, subject to closing conditions including a minimum tender and net cash threshold.
Strategic review led to a 70% workforce reduction and asset sales, including the Sec61-based program to Enodia for $1M upfront and potential milestones up to $127M.
If the merger is not completed, alternatives include dissolution and liquidation, with cash available for distribution to stockholders.
Financial highlights
Net loss for Q1 2026 was $5.8M, a significant improvement from $16.6M in Q1 2025, driven by lower R&D and G&A expenses.
Operating expenses dropped to $7.4M from $17.7M year-over-year, mainly due to reduced clinical and personnel costs.
Cash and cash equivalents stood at $66.2M as of March 31, 2026.
No product revenue; collaboration revenue recognized in prior periods from Everest Medicines.
Outlook and guidance
Cash runway expected to cover at least 12 months from the reporting date.
R&D and G&A expenses projected to remain flat or decrease for the remainder of 2026 due to program suspensions and reduced headcount.
Future funding needs depend on merger completion and realization of cost reductions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kezar Life Sciences
- Net loss narrowed to $56M in 2025 as restructuring and strategic review efforts continued.KZR
Q4 2025 - Biotech seeks $400M to advance immune disease drug, leveraging strong governance and flexible funding.KZRRegistration Filing
- Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.KZRProxy Filing
- Key votes: director elections, executive pay, and auditor ratification for 2025.KZRProxy Filing
- Net loss narrowed in Q3 2025 amid restructuring, strategic review, and major cost reductions.KZRQ3 2025
- Net loss narrowed, liquidity strong, and focus shifts to autoimmune hepatitis after trial termination.KZRQ3 2024
- Net loss narrowed in Q2 2024; zetomipzomib prioritized and cash runway extends 12 months.KZRQ2 2024
- Zetomipzomib achieved durable, steroid-sparing remissions in refractory AIH, supporting further trials.KZRQ4 2024 & Study Result
- Zidomipzomib delivers promising remission rates in refractory AIH, with pivotal trial plans advancing.KZRJefferies Global Healthcare Conference 2025
Kezar Life Sciences
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kezar Life Sciences Inc. is a biotechnology company focused on developing therapies for autoimmune diseases and cancer. The company specializes in small-molecule drug candidates targeting protein homeostasis and immune system regulation. Its research and development efforts aim to advance treatments for conditions such as lupus nephritis and other immune-mediated disorders through clinical trials. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.